A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)
It is a phase Ⅱ,open-label, single-line, Multiple cohorts, Multicenter study assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins mutation patients with Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC).
Non-Small-Cell Lung Cancer
DRUG: PLB1004
objective Response Rate (ORR), To evaluate the Objective Response Rate（ORR）which is defined by IRC as the proportion of subjects with confirmed best overall response of complete response or partial response per RECIST v 1.1., 3 years
objective Response Rate (ORR), To evaluate the Overall Response Rate（ORR）which is defined by investigator as the proportion of subjects with confirmed best overall response of complete response or partial response per RECIST v 1.1., 3 years|Disease Control Rate ( DCR), DCR is defined as the percentage of participants achieving complete or partial response or stable disease of at least 11 weeks as defined per RECIST v 1.1, 3 years|Duration of Response (DOR), DOR is defined as the time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first., 3 years|Progression-Free Survival (PFS), PFS is defined as the time from the date the first dose until the date of objective disease progression or death by cause, whichever comes first, based on investigator review according to RECISTv1.1., 3 years|Overall Survival (OS), OS is defined as the time from the date of the first dose until the date of death due to any cause., 3 years|Intracranial Overall Response Rate（ORR）, To evaluate the intracranial Overall Response Rate（ORR）which is defined by investigator as the proportion of subjects with Intracranial disease confirmed best overall response of complete response or partial response per RECIST v 1.1., 3 years|Intracranial Disease Control Rate (DCR), Intracranial DCR is defined as the percentage of participants achieving Intracranial disease complete or partial response or stable disease of at least 11 weeks as defined per RECIST v 1.1., 3 years|Intracranial Disease Control Rate (DOR), Intracranial DOR is defined as the time from the date of first documented response (CR or PR) until the date of Intracranial disease documented progression or death, whichever comes first., 3 years|Intracranial Progression-Free Survival (PFS), Intracranial PFS is defined as the time from the date the first dose until the date of objective disease progression or death by cause, whichever comes first, based on investigator review according to RECISTv1.1., 3 years|Incidence of Treatment-Emergent Adverse Events (TEAEs), A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug assessed by CTCAE v5.0., 2 years|Incidence of abnormalities in Clinical Laboratory Assessments., Number of participants with abnormalities in Clinical Laboratory tests（including serum chemistry and hematology） will be reported., 2 years|Incidence of abnormalities in Vital Signs., Number of participants with abnormalities in vital signs(including temperature ,pulse/heart rate，and blood pressure) will be reported., 2 years|Area Under the Curve（AUC0-t）of PLB1004, The AUC values are based on the plasma concentration-time profile (from time 0 to Time of the Last Quantifiable Concentration) of PLB1004. To characterize the pharmacokinetics of PLB1004., Time Frame: Up to approximately 28 days; pre-dose and multiple time points post-dose|Area Under the Curve（AUC0-∞）of PLB1004, The AUC values are based on the plasma concentration-time profile (from time 0 to infinity) of PLB1004. To characterize the pharmacokinetics of PLB1004., Time Frame: Up to approximately 28 days; pre-dose and multiple time points post-dose|Maximum plasma concentration (Cmax) of PLB1004, The Cmax values are based on the plasma concentration-time profile of PLB1004. To characterize the pharmacokinetics of PLB1004., Time Frame: Up to approximately 28 days; pre-dose and multiple time points post-dose|Time to maximum plasma concentration (Tmax) of PLB1004, The Tmax values are based on the plasma concentration-time profile of PLB 1004.To characterize the pharmacokinetics of PLB1004., Time Frame: Up to approximately 28 days; pre-dose and multiple time points post-dose|Half-life time (t1/2) of PLB1004, The t1/2 values are based on the terminal disposition Phase Half-life for PLB1004 and its Active Metabolites. To characterize the pharmacokinetics of PLB1004., Time Frame: Up to approximately 28 days; pre-dose and multiple time points post-dose|Apparent clearance (CL/F) of PLB1004, The CL/F values are based on the apparent clearance after extravascular administration for PLB1004. To characterize the pharmacokinetics of PLB1004., Time Frame: Up to approximately 28 days; pre-dose and multiple time points post-dose
This a three-stage study consist a Screening Phase (Day -28 to -1), a Treatment Phase (until treatment discontinuation), and a Follow-up Phase (including end of treatment visit (EOT),end of study visit(EOS), safety follow-up and survival follow-up).